Is BEAT or AMWL more profitable?

HeartBeam has a net margin of 0.00% compared to American Well's net margin of -37.02%. American Well's return on equity of -32.11% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets HeartBeam N/A -1,034.04% -434.40% American Well -37.02% -32.11% -24.12%

Is BEAT or NYXH more profitable?

HeartBeam has a net margin of 0.00% compared to Nyxoah's net margin of -543.21%. Nyxoah's return on equity of -163.73% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets HeartBeam N/A -1,034.04% -434.40% Nyxoah -543.21% -163.73% -80.24%

Is BEAT or ZEPP more profitable?

HeartBeam has a net margin of 0.00% compared to Zepp Health's net margin of -14.70%. Zepp Health's return on equity of -15.15% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets HeartBeam N/A -1,034.04% -434.40% Zepp Health -14.70% -15.15% -5.94%

Which has preferable earnings and valuation, BEAT or CCLD?

CareCloud has higher revenue and earnings than HeartBeam. HeartBeam is trading at a lower price-to-earnings ratio than CareCloud, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HeartBeam N/A N/A -$21.01M -$0.56 N/A CareCloud $120.50M 0.81 $10.80M $0.11 20.86

Is BEAT or CCLD more profitable?

CareCloud has a net margin of 7.87% compared to HeartBeam's net margin of 0.00%. CareCloud's return on equity of 24.05% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets HeartBeam N/A -1,034.04% -434.40% CareCloud 7.87% 24.05% 16.38%

HeartBeam (BEAT) Competitors

$0.76 -0.01 (-0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$0.77 +0.01 (+1.56%)

As of 05:11 PM Eastern

Compare

BEAT vs. KRMD, AMWL, NYXH, ZEPP, and CCLD

Should you buy HeartBeam stock or one of its competitors? MarketBeat compares HeartBeam with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HeartBeam include KORU Medical Systems (KRMD), American Well (AMWL), Nyxoah (NYXH), Zepp Health (ZEPP), and CareCloud (CCLD). These companies are all part of the "medical info sys" industry.

How does HeartBeam compare to KORU Medical Systems?

KORU Medical Systems (NASDAQ:KRMD) and HeartBeam (NASDAQ:BEAT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

HeartBeam has a net margin of 0.00% compared to KORU Medical Systems' net margin of -5.27%. KORU Medical Systems' return on equity of -13.61% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KORU Medical Systems	-5.27%	-13.61%	-8.33%
HeartBeam	N/A	-1,034.04%	-434.40%

KORU Medical Systems currently has a consensus target price of $7.25, indicating a potential upside of 81.25%. HeartBeam has a consensus target price of $4.33, indicating a potential upside of 471.53%. Given HeartBeam's stronger consensus rating and higher possible upside, analysts plainly believe HeartBeam is more favorable than KORU Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KORU Medical Systems	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

In the previous week, KORU Medical Systems and KORU Medical Systems both had 1 articles in the media. KORU Medical Systems' average media sentiment score of 1.89 equaled HeartBeam'saverage media sentiment score.

Company	Overall Sentiment
KORU Medical Systems	Very Positive
HeartBeam	Very Positive

KORU Medical Systems has higher revenue and earnings than HeartBeam. KORU Medical Systems is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KORU Medical Systems	$43.26M	4.25	-$2.64M	-$0.05	N/A
HeartBeam	N/A	N/A	-$21.01M	-$0.56	N/A

KORU Medical Systems has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, HeartBeam has a beta of -0.86, meaning that its stock price is 186% less volatile than the broader market.

58.6% of KORU Medical Systems shares are owned by institutional investors. Comparatively, 7.8% of HeartBeam shares are owned by institutional investors. 18.5% of KORU Medical Systems shares are owned by insiders. Comparatively, 18.0% of HeartBeam shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

KORU Medical Systems beats HeartBeam on 8 of the 13 factors compared between the two stocks.

How does HeartBeam compare to American Well?

HeartBeam (NASDAQ:BEAT) and American Well (NYSE:AMWL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

HeartBeam has a net margin of 0.00% compared to American Well's net margin of -37.02%. American Well's return on equity of -32.11% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-1,034.04%	-434.40%
American Well	-37.02%	-32.11%	-24.12%

HeartBeam currently has a consensus price target of $4.33, suggesting a potential upside of 471.53%. American Well has a consensus price target of $7.20, suggesting a potential downside of 20.97%. Given HeartBeam's stronger consensus rating and higher probable upside, equities research analysts plainly believe HeartBeam is more favorable than American Well.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
American Well	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, HeartBeam and HeartBeam both had 1 articles in the media. HeartBeam's average media sentiment score of 1.89 beat American Well's score of 0.36 indicating that HeartBeam is being referred to more favorably in the media.

Company	Overall Sentiment
HeartBeam	Very Positive
American Well	Neutral

HeartBeam has a beta of -0.86, indicating that its share price is 186% less volatile than the broader market. Comparatively, American Well has a beta of 1.69, indicating that its share price is 69% more volatile than the broader market.

7.8% of HeartBeam shares are held by institutional investors. Comparatively, 56.0% of American Well shares are held by institutional investors. 18.0% of HeartBeam shares are held by insiders. Comparatively, 12.8% of American Well shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

HeartBeam has higher earnings, but lower revenue than American Well. American Well is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.56	N/A
American Well	$237.38M	0.64	-$95.70M	-$5.42	N/A

Summary

HeartBeam beats American Well on 10 of the 15 factors compared between the two stocks.

How does HeartBeam compare to Nyxoah?

HeartBeam (NASDAQ:BEAT) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

HeartBeam has higher earnings, but lower revenue than Nyxoah. HeartBeam is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.56	N/A
Nyxoah	$11.33M	5.10	-$101.92M	-$2.48	N/A

HeartBeam presently has a consensus target price of $4.33, indicating a potential upside of 471.53%. Nyxoah has a consensus target price of $7.67, indicating a potential upside of 414.54%. Given HeartBeam's stronger consensus rating and higher probable upside, equities research analysts plainly believe HeartBeam is more favorable than Nyxoah.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

HeartBeam has a beta of -0.86, meaning that its share price is 186% less volatile than the broader market. Comparatively, Nyxoah has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market.

7.8% of HeartBeam shares are held by institutional investors. 18.0% of HeartBeam shares are held by company insiders. Comparatively, 17.1% of Nyxoah shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

HeartBeam has a net margin of 0.00% compared to Nyxoah's net margin of -543.21%. Nyxoah's return on equity of -163.73% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-1,034.04%	-434.40%
Nyxoah	-543.21%	-163.73%	-80.24%

In the previous week, Nyxoah had 8 more articles in the media than HeartBeam. MarketBeat recorded 9 mentions for Nyxoah and 1 mentions for HeartBeam. HeartBeam's average media sentiment score of 1.89 beat Nyxoah's score of 0.28 indicating that HeartBeam is being referred to more favorably in the media.

Company	Overall Sentiment
HeartBeam	Very Positive
Nyxoah	Neutral

Summary

HeartBeam beats Nyxoah on 10 of the 16 factors compared between the two stocks.

How does HeartBeam compare to Zepp Health?

HeartBeam (NASDAQ:BEAT) and Zepp Health (NYSE:ZEPP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

In the previous week, Zepp Health had 7 more articles in the media than HeartBeam. MarketBeat recorded 8 mentions for Zepp Health and 1 mentions for HeartBeam. HeartBeam's average media sentiment score of 1.89 beat Zepp Health's score of 0.34 indicating that HeartBeam is being referred to more favorably in the media.

Company	Overall Sentiment
HeartBeam	Very Positive
Zepp Health	Neutral

7.8% of HeartBeam shares are held by institutional investors. Comparatively, 52.6% of Zepp Health shares are held by institutional investors. 18.0% of HeartBeam shares are held by insiders. Comparatively, 36.0% of Zepp Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

HeartBeam has a beta of -0.86, meaning that its stock price is 186% less volatile than the broader market. Comparatively, Zepp Health has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market.

HeartBeam has higher earnings, but lower revenue than Zepp Health. Zepp Health is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.56	N/A
Zepp Health	$271.91M	0.26	-$40.07M	-$2.52	N/A

HeartBeam has a net margin of 0.00% compared to Zepp Health's net margin of -14.70%. Zepp Health's return on equity of -15.15% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-1,034.04%	-434.40%
Zepp Health	-14.70%	-15.15%	-5.94%

HeartBeam currently has a consensus price target of $4.33, indicating a potential upside of 471.53%. Zepp Health has a consensus price target of $56.28, indicating a potential upside of 1,079.87%. Given Zepp Health's higher possible upside, analysts plainly believe Zepp Health is more favorable than HeartBeam.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Zepp Health	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

HeartBeam and Zepp Health tied by winning 8 of the 16 factors compared between the two stocks.

How does HeartBeam compare to CareCloud?

HeartBeam (NASDAQ:BEAT) and CareCloud (NASDAQ:CCLD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

CareCloud has a net margin of 7.87% compared to HeartBeam's net margin of 0.00%. CareCloud's return on equity of 24.05% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-1,034.04%	-434.40%
CareCloud	7.87%	24.05%	16.38%

In the previous week, CareCloud had 3 more articles in the media than HeartBeam. MarketBeat recorded 4 mentions for CareCloud and 1 mentions for HeartBeam. HeartBeam's average media sentiment score of 1.89 beat CareCloud's score of 0.97 indicating that HeartBeam is being referred to more favorably in the media.

Company	Overall Sentiment
HeartBeam	Very Positive
CareCloud	Positive

CareCloud has higher revenue and earnings than HeartBeam. HeartBeam is trading at a lower price-to-earnings ratio than CareCloud, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.56	N/A
CareCloud	$120.50M	0.81	$10.80M	$0.11	20.86

7.8% of HeartBeam shares are owned by institutional investors. Comparatively, 10.2% of CareCloud shares are owned by institutional investors. 18.0% of HeartBeam shares are owned by company insiders. Comparatively, 14.8% of CareCloud shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

HeartBeam has a beta of -0.86, indicating that its share price is 186% less volatile than the broader market. Comparatively, CareCloud has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

HeartBeam currently has a consensus target price of $4.33, indicating a potential upside of 471.53%. CareCloud has a consensus target price of $3.25, indicating a potential upside of 41.61%. Given HeartBeam's stronger consensus rating and higher possible upside, research analysts clearly believe HeartBeam is more favorable than CareCloud.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
CareCloud	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

CareCloud beats HeartBeam on 10 of the 16 factors compared between the two stocks.

Get HeartBeam News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BEAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BEAT vs. The Competition

Export

Metric	HeartBeam	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$42.09M	$1.53B	$6.51B	$11.99B
Dividend Yield	N/A	N/A	2.67%	5.62%
P/E Ratio	-1.35	77.53	24.24	24.13
Price / Sales	N/A	6.63	473.83	85.01
Price / Cash	N/A	23.11	43.05	54.72
Price / Book	12.64	4.88	10.49	6.82
Net Income	-$21.01M	-$54.76M	$3.56B	$337.52M
7 Day Performance	-16.27%	-6.93%	-2.01%	-0.93%
1 Month Performance	-14.50%	2.59%	0.67%	1.70%
1 Year Performance	-51.08%	-9.89%	21.86%	26.89%

HeartBeam Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BEAT HeartBeam	3.9942 of 5 stars	$0.76 -0.7%	$4.33 +471.5%	-51.8%	$42.09M	N/A	N/A	1,700	Positive News Gap Up
KRMD KORU Medical Systems	4.19 of 5 stars	$4.00 -1.2%	$7.25 +81.3%	+24.4%	$183.72M	$41.13M	N/A	80
AMWL American Well	2.152 of 5 stars	$8.21 -3.4%	$7.13 -13.2%	+13.9%	$135.88M	$249.32M	N/A	1,040	Analyst Forecast
NYXH Nyxoah	2.7363 of 5 stars	$2.89 -2.7%	$7.67 +165.3%	-83.2%	$112.02M	$15.33M	N/A	110	News Coverage Gap Up
ZEPP Zepp Health	2.8065 of 5 stars	$6.97 -8.3%	$56.28 +707.5%	+64.7%	$102.32M	$258.90M	N/A	1,230	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BEAT) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HeartBeam (BEAT) Competitors

BEAT vs. KRMD, AMWL, NYXH, ZEPP, and CCLD

How does HeartBeam compare to KORU Medical Systems?

Summary

How does HeartBeam compare to American Well?

Summary

How does HeartBeam compare to Nyxoah?

Summary

How does HeartBeam compare to Zepp Health?

Summary

How does HeartBeam compare to CareCloud?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAT vs. The Competition

HeartBeam Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HeartBeam (BEAT) Competitors

BEAT vs. KRMD, AMWL, NYXH, ZEPP, and CCLD

How does HeartBeam compare to KORU Medical Systems?

Is KRMD or BEAT more profitable?

Do analysts prefer KRMD or BEAT?

Does the media refer more to KRMD or BEAT?

Which has stronger earnings & valuation, KRMD or BEAT?

Which has more volatility & risk, KRMD or BEAT?

Do insiders & institutionals believe in KRMD or BEAT?

Summary

How does HeartBeam compare to American Well?

Is BEAT or AMWL more profitable?

Do analysts recommend BEAT or AMWL?

Does the media favor BEAT or AMWL?

Which has more volatility & risk, BEAT or AMWL?

Do insiders and institutionals hold more shares of BEAT or AMWL?

Which has stronger earnings and valuation, BEAT or AMWL?

Summary

How does HeartBeam compare to Nyxoah?

Which has better valuation and earnings, BEAT or NYXH?

Do analysts prefer BEAT or NYXH?

Which has more risk & volatility, BEAT or NYXH?

Do insiders and institutionals believe in BEAT or NYXH?

Is BEAT or NYXH more profitable?

Does the media prefer BEAT or NYXH?

Summary

How does HeartBeam compare to Zepp Health?

Does the media favor BEAT or ZEPP?

Do insiders & institutionals believe in BEAT or ZEPP?

Which has more risk and volatility, BEAT or ZEPP?

Which has higher earnings & valuation, BEAT or ZEPP?

Is BEAT or ZEPP more profitable?

Do analysts prefer BEAT or ZEPP?

Summary

How does HeartBeam compare to CareCloud?

Is BEAT or CCLD more profitable?

Does the media prefer BEAT or CCLD?

Which has preferable earnings and valuation, BEAT or CCLD?

Do insiders and institutionals believe in BEAT or CCLD?

Which has more volatility & risk, BEAT or CCLD?

Do analysts rate BEAT or CCLD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAT vs. The Competition

HeartBeam Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools